Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047807 | 0.67 | MMP9 (0.33) | MMP9 | |
| SCHEMBL2051235 | 0.64 | MMP9 (0.36) | MMP9CYP3A4 | |
| SCHEMBL25957 | 0.62 | MMP9 (0.46) | MMP9NR1I2CYP3A4 | |
| SCHEMBL828185 | 0.62 | ALDH1A1 (0.33) | ALDH1A1MAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL829889 | 0.61 | MAPT (0.34) | ALDH1A1MAPT | |
| SCHEMBL2049685 | 0.60 | GABRA1 (0.41) | MMP9 | |
| SCHEMBL14788952 | 0.59 | MMP9 (0.50) | MMP9ALDH1A1NR1I2CYP3A4 | |
| SCHEMBL15974732 | 0.59 | GABRA1 (0.40) | MMP9 | |
| SCHEMBL10587993 | 0.59 | MMP9 (0.32) | MMP9 | |
| SCHEMBL10281706 | 0.58 | CYP3A4 (0.60) | MMP9ALDH1A1MAPTNR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1067942-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | Cyclops, EHF. (IS) | 2001-01-17 | — | — | EP | claimed |
| WO-1999042111-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | CYCLOPS, EHF. (IS) | 1999-08-26 | — | — | WO | claimed |
| US-20040186075-A1 | High-energy cyclodextrin complexes | LOFTSSON THORSTEINN (IS) | 2004-09-23 | — | — | US | disclosed |
| US-6699849-B1 | BIOAVAILABILITY | CYCLOPS, EHF. (IS) | 2004-03-02 | — | — | US | disclosed |
| EP-1067942-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | Cyclops, EHF. (IS) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999042111-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | CYCLOPS, EHF. (IS) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186075-A1 | High-energy cyclodextrin complexes | GYS2, SI, GYS1 | MMP9 4838/4885ALDH1A1 4506/4885MAPT 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.